IP Library Granted Patent US 7,674,830
Granted Patent B2
US 7,674,830 · App. 10/462,030 · Granted Mar 9, 2010

Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent

Assignee: Unigen Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,674,830
App. No.
10/462,030
Granted
Mar 9, 2010
Kind
B2
Abstract

The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) enzymes, and reducing cox-2 mRNA production. Finally, the present invention includes a method for weight loss and blood glucose control. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier. This invention relates generally to the prevention and treatment of diseases and conditions mediated by the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) pathways, including but not limited to the relief joint discomfort and pain associated with conditions such as osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse.

Claims (2)

1. A method for decreasing body mass index and causing weight loss said method comprising administering to a host in need thereof an effective amount of a composition consisting essentially of baicalin and catechin, wherein said composition is administered in a dosage selected from 0.01 to 200 mg/kg of body weight.

2. The method of claim 1 wherein the routes of the administration are selected from the group consisting of oral, topical, suppository, intravenous, and intradermic, intragaster, intramusclar, intraperitoneal and intravenous administration.

Assignments (2)
CHANGE OF NAME Recorded Oct 4, 2011
From: UNIGEN PHARMACEUTICALS, INC.
To: UNIGEN, INC.
Reel/Frame 027015/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2003
From: JIA, QI
To: UNIGEN PHARMACEUTICALS, INC.
Reel/Frame 013848/0888 →
Continuity (3)
Continuation 1042774600 · Apr 30, 2003
Provisional Application 6037716800 · Apr 30, 2002
Related Publication 20030232763A1 · Dec 18, 2003